Group One Trading
VRDN icon

Group One Trading’s Viridian Therapeutics VRDN Stock Holding History

Group One Trading’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-625
Closed -$10.1K – 8599
2026
Q1 		$12.2K Buy
625
+396
+173% +$11.8K ﹤0.01% 6256
2025
Q4 		$7.13K Buy
+229
New +$6.28K ﹤0.01% 7003
2025
Q1 		– Sell
-47,995
Closed -$818K – 8434
2024
Q4 		$920K Buy
47,995
+7,233
+18% +$157K ﹤0.01% 2647
2024
Q3 		$927K Buy
40,762
+30,898
+313% +$505K ﹤0.01% 2365
2024
Q2 		$128K Buy
+9,864
New +$137K ﹤0.01% 3758
2024
Q1 		– Sell
-17
Closed -$330 – 8030
2023
Q4 		$370 Sell
17
-2,628
-99% -$41.5K ﹤0.01% 7120
2023
Q3 		$40.6K Sell
2,645
-3,817
-59% -$72.8K ﹤0.01% 5297
2023
Q2 		$154K Buy
+6,462
New +$166K ﹤0.01% 4205

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Group One Trading's VRDN Position: Q2 2026 in Review

Group One Trading sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 625 shares — an estimated $10.1K sold.

Group One Trading first reported a position in VRDN in Q2 2023 and held it in 8 quarters. The position peaked at $927K in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Group One Trading reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 625 Viridian Therapeutics shares in Q2 2026, an estimated $10.1K.
  • Group One Trading first reported a position in Viridian Therapeutics in Q2 2023 and held it in 8 quarters.
  • Group One Trading's Viridian Therapeutics position peaked at $927K in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.